ReviewEndocrinology, diabetes & metabolism2026
Gene-Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium-Glucose Cotransporter-2 Inhibitors.
Review in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInter-individual variability in the therapeutic response to antidiabetic drugs is still a big problem in the management of type 2 diabetes mellitus (T2DM). Genetic polymorphisms of drug transporters, metabolizing enzymes and molecular targets have become significant factors in drug efficacy, pharmacokinetics and adverse effects. This review aims to provide a summary of the current evidence on the pharmacogenomics of metformin and sodium-glucose cotransporter-2 (SGLT2) inhibitors and their implications for precision medicine in T2DM.
methodsPublished human studies examining genetic polymorphisms related to the various effects of metformin and SGLT2 inhibitors in patients with T2DM were systematically searched in PubMed, Scopus and EBSCO and analysed using an integrative review. Qualitative synthesis was used to compare the pharmacogenetic profiles of the two drug classes and to look for potential biomarkers for precision therapy.
resultsMetformin has the most comprehensive pharmacogenetic evidence, including variants in SLC22A1 (OCT1), SLC22A2 (OCT2), SLC22A3 (OCT3), SLC47A1 (MATE1), SLC47A2 (MATE2), ATM and other genes that affect drug disposition, glycemic response and adverse effects. However, pharmacogenetic research on SGLT2 inhibitors is still scarce. Modest variations in drug exposure, glucose homeostasis and cardiorenal or hepatic outcomes have been reported for variants of UGT1A9, UGT2B4, SLC5A2, PNPLA3, and some glucose transporters, but most of these effects have not been strong enough to recommend routine genotype-based therapy. Metformin has more robust and consistent pharmacogenetic associations overall, while SGLT2 inhibitors have emerging but less definitive associations.
conclusionPharmacogenomics has great promise to enhance the selection of antidiabetic drugs, maximize therapeutic effect and minimize side effects. There is current evidence for the clinical relevance of several pharmacogenetic markers for metformin, but evidence for SGLT2 inhibitors is preliminary. Further, large, prospective, multiethnic studies and genotype-based clinical trials are needed to confirm candidate biomarkers and to help incorporate pharmacogenomics into precision medicine for T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.